Leaflet KEYTRUDA 50mg powder for concentrate for solution for infusion
Indicated for: cancer
Route of administration: infusion
Substance: pembrolizumab (monoclonal antibody)
ATC: L01FF02 (Antineoplastic and immunomodulating agents | Monoclonal antibodies and antibody drug conjugates | Pd-1/pdl-1 (programmed cell death protein 1/death ligand 1) inhibitors)
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
Seek medical advice if severe or persistent diarrhea occurs.
This medicine is subject to additional monitoring.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
Pembrolizumab is a monoclonal antibody used in cancer immunotherapy, including the treatment of melanoma, lung cancer, and other types of cancer. It works by blocking the PD-1 receptor, allowing the immune system to recognize and destroy tumor cells.
The medication is administered intravenously, as directed by a doctor, usually once every three or six weeks. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the response to therapy.
Patients should be aware of potential side effects, such as fatigue, diarrhea, or skin reactions. It is important to inform the doctor of any unusual symptoms.
Common side effects include fatigue, diarrhea, and skin reactions. In rare cases, severe reactions such as immune-related toxicity or allergic reactions may occur. Patients should be informed of these risks before use.
General data about KEYTRUDA 50mg
- Substance: pembrolizumab
- Date of latest medicines list: 01-12-2022
- Product code: W64587001
- Concentration: 50mg
- Pharmaceutical form: powder for concentrate for solution for infusion
- Quantity: 1
- Product type: Original
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for pembrolizumab
Concentrations available for pembrolizumab
- 25mg/ml
- 395mg
- 50mg
- 790mg